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ABSTRACT  
Background: Although prior studies showed metformin could reduce gastric cancer (GC) 
risk in patients with diabetes mellitus (DM), they failed to adjust for Helicobacter pylori 
infection and glycemic control. We aimed to investigate whether metformin reduced GC risk 
in H. pylori -eradicated diabetic patients and its association with glycemic control. 
Methods: This was a territory-wide cohort study using hospital registry database, recruiting 
all diabetic patients who were prescribed clarithromycin-based triple therapy for H. pylori 
infection from 2003 to 2012. Subjects were observed from H. pylori therapy prescription 
until GC diagnosis, death or end of study (December 2015). Exclusion criteria included GC 
diagnosed within first year of H. pylori therapy, prior history of GC or gastrectomy, and 
failure of H. pylori eradication. The hazard ratio (HR) of GC with metformin (defined as at 
least 180-day use) was estimated by Cox model with propensity score adjustment for 
covariates (age, sex, comorbidities, medications [including insulin], and time-weighted 
average hemoglobin A1c [HbA1c]). All statistical tests were two-sided.  
Results: During a median follow-up of 7.1 years (IQR:4.7–9.8), 37 (0.51%) of 7,266 diabetic 
patients developed GC at a median age of 76.4 years (IQR: 64.8–81.5 years). Metformin use 
was associated with a reduced GC risk (adjusted HR:0.49; 95% CI:0.24–0.98). There was a 
trend towards a lower GC risk with increasing duration (ptrend =0.01) and dose of metformin 
(ptrend=0.02). HbA1c level was not an independent risk factor for GC. 
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Conclusions: Metformin use was associated with a lower GC risk among H. pylori -
eradicated diabetic patients in a duration- and dose-response manner, which was independent 
of HbA1c level.  
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INTRODUCTION 
Gastric cancer (GC) is the fifth commonest cancer and the third leading cause of cancer-
related mortality worldwide.(1) Helicobacter pylori (H. pylori) infection is the major risk 
factor for GC(2). However, H. pylori eradication could only reduce GC risk by approximately 
40% (3-5). Apart from H. pylori, diabetes mellitus (DM) has been reported to increase GC 
risk by approximately 20%.(6) As DM is a very prevalent medical condition with more than 
12% of adult population being affected,(7) the burden of GC cases attributed to DM could be 
substantial.  
Metformin, a biguanide, is frequently used to treat DM. Apart from its effect on 
glycemic control, metformin has anti-cancer effect associated with insulin sensitization, 
reducing hyperinsulinemia and insulin-growth factor (IGF) production, both of which shown 
to enhance proliferation of cancer cells that express IGF receptors.(8) Metformin also 
activates AMP-activated protein kinase (AMPK) which suppresses cancer cell growth by 
inhibiting the mammalian target of rapamycin pathway.(9) The chemopreventive role of 
metformin in GC, however, remains controversial. While no association between metformin 
use and GC was reported by some studies,(10, 11) others suggested a protective effect with 
varying effect estimates.(12-16) A recent meta-analysis(17) concluded that metformin 
decreased GC risk by 24% but there was a statistically significant heterogeneity among 
studies. More importantly, other important risk factors of GC including H. pylori infection 
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and DM severity have not been adequately addressed in previous studies, potentially 
undermining the role of metformin on GC prevention.(17) As H. pylori is the most important 
risk factor of GC, failure to stratify patients according to H. pylori status will affect the true 
effect estimate of metformin on GC development. Moreover, GC risk was shown to be higher 
among individuals with higher hemoglobin A1c (HbA1c) levels(18). The beneficial effect of 
metformin on reducing GC could be mediated via improving DM control rather than the 
proposed anti-cancer mechanisms.  
With the use of a large cohort of diabetic patients who had received H. pylori 
eradication therapy, we aimed to investigate the potential chemopreventive effect of 
metformin on GC in diabetic patients who had received H. pylori eradication therapy, and 
whether higher HbA1c level was associated with an increased GC risk. 
 
METHODS 
Data source  
This was a territory-wide cohort study using data retrieved from the Clinical Data Analysis 
and Reporting System (CDARS) of the Hong Kong Hospital Authority. The Hospital 
Authority is the governing body of all public hospitals and clinics in Hong Kong with a 
population of 7.3 million, and a 90% coverage of all primary, secondary and tertiary care 
during the study period (2003–2015).(19) Patient’s data including demographics, diagnoses, 
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drug dispensing records, procedures and laboratory results, hospitalization, attendance of 
outpatient clinics and emergency departments, and death are all accessible in the 
CDARS.(20-25) Diagnoses are coded in accordance with the International Classification of 
Diseases, Ninth Revision (ICD-9). Prior studies using this electronic registry database 
showed high coding accuracy with positive and negative predictive values of > 90.(21, 26) 
Individuals’ information is anonymized with a unique reference key to protect patient’s 
confidentiality. The study was approved by the Institutional Review Board of the University 
of Hong Kong and the West Cluster of Hospital Authority, Hong Kong (reference no: UW 
16-545).  
 
Study Subjects  
All adult patients aged 18 years or above with a baseline diagnosis of DM who were 
dispensed a course of clarithromycin-based triple therapy for H. pylori between 1 January 
2003 and 31 December 2012 were identified. The diagnosis of DM was based on the ICD-9 
codes of DM (ICD-9 codes: 249 and 250). The prescription of clarithromycin-based triple 
therapy included the co-prescription of one of the proton pump inhibitors (PPIs) with 
clarithromycin and either amoxicillin or metronidazole with the correct doses, same 
prescription start dates and a treatment duration of 7-14 days.(27) With the high H. pylori 
eradication rate (> 90%) and low resistance rate to clarithromycin (8%) in Hong Kong(28), 
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clarithromycin-based triple therapy was the first-line H. pylori treatment during the study 
period.(29) A diagnosis of H. pylori infection was made by either biopsy-based tests (rapid 
urease test and histology) or urea breath test, as other diagnostic modalities were not 
available in the public hospitals. Exclusion criteria included: gastric lymphoma; GC 
diagnosed within the first year of H. pylori eradication therapy (as there was a possibility of 
delayed or missed diagnosis); prior history of GC; prior gastrectomy; and failure of H. pylori 
eradication. Because there was no ICD-9 code for failure of H. pylori eradication, this could 
only be inferred from the repeated prescription of clarithromycin-based triple therapy, or 
subsequent prescriptions of either a second-line therapy (either PPI-levofloxacin-amoxycillin 
or bismuth-based quadruple therapy), or a third-line therapy (rifabutin-based therapy). The 
patient selection process is illustrated in Supplementary Figure 1. 
 
Study Outcome 
Gastric adenocarcinoma after H. pylori eradication therapy was identified by the ICD-9 
coding (Supplementary Table 1). The validation of the GC diagnosis and final H. pylori 
status of these cancer patients had been validated in our previous studies, with 100% 
accuracy.(30) The observation period started from the first date of H. pylori therapy 
prescription (i.e. index date), and censored at GC diagnosis, death or end of study (December 
 9 
2015). The earliest date of hospitalization for cancer workup or treatment was regarded as the 
GC diagnosis date.  
 
Metformin, insulin and other covariates  
We defined metformin use as more than 180-day use [as proposed by Kim et al(13)] after 
receiving H. pylori eradication therapy. To study the dose-response relationship of metformin 
on GC risk, cumulative defined daily dose (cDDD) as per the World Health Organization 
Collaborating Center for Drug Statistics Methodology (31) was calculated by summing the 
dispensed DDDs of metformin during the study observation period, and categorized into non-
metformin use, use of cDDDs below the median, and use of cDDDs equal to or above the 
median. To study the duration-response relationship, the duration of metformin use was 
divided into three groups: non-metformin use, <3 years, and ≥3 years, as defined previously 
by Kim et al.(13)  
Potential risk factors for GC included the age of receiving H. pylori eradication 
therapy, gender, smoking and alcohol use, past history of peptic ulcer disease, other 
comorbidities (atrial fibrillation, ischemic heart disease, congestive heart failure, chronic 
renal failure, cirrhosis, stroke, dyslipidemia, hypertension and obesity) and concurrent 
medications uses (aspirin, non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-
2 [COX-2] inhibitors,(32, 33) statins,(34) PPIs,(30, 35) insulin(36, 37)) and HbA1c(18) were 
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considered during analysis. Smoking and alcohol statuses were ascertained as reported 
previously.(38) Smoking was identified by the documentation of the smoking status in the 
CDARS, the ICD-9 code of V15.82 or indirectly by the presence of chronic obstructive 
pulmonary disease (COPD). Alcohol use was signified by the presence of alcohol-related 
diseases, comprising gastrointestinal, hepatic, psychiatric and neurological diseases. Obesity 
was identified by the ICD-9 codes of 278.0 and 278.1 or a body mass index 25 kg/m2. 
eTable 1 shows the diagnostic codes of all variables. In order to adjust for the bias due to 
irregular interval measurements, time-weighted average HbA1c was used to represent the 
overall glycemic control during the observation period as described by Yip et al.(39) This 
was derived as the average HbA1c weighted by the time interval between successive 
measurements. We categorized the time-weighted average HbA1c into a binary variable by a 
cut-off value of 7% as individuals with HbA1c ≥7% were at a higher risk of GC than subjects 
without DM in a previous population-based cohort study.(18) For consistency, we used a cut-
off of 180 days to define the use of other medications. We also investigated the association 
between insulin use and GC, as IGFs have been proposed to be involved in GC 
development.(36, 37, 40)  
 
Statistical analyses  
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All statistical analyses were performed using R version 3.2.3 (R Foundation for Statistical 
Computing) statistical software. Continuous variables were expressed as median with 
interquartile range (IQR) and categorical variables were presented as number (percentage). 
Comparison of two groups was analyzed by Mann-Whitney U-test for continuous variables, 
and Chi-square or Fisher’s exact test for categorical variables. The Cox proportional hazards 
model was used to determine the hazard ratio (HR) of GC with metformin use. We checked 
whether the Cox proportional-hazard assumption was fulfilled by a ‘complementary log-log’-
scaled Kaplan-Meier plot and schoenfeld residuals (p-value > 0.05; which indicated no 
interaction of the covariates with time). 
Propensity score (PS) adjustment was used to control for selection bias due to 
different baseline characteristics. The PS was estimated by multivariable logistic regression 
based on the aforementioned covariates, and represents the probability of prescribing 
metformin to an individual given the covariates. As such, any difference in GC risk would be 
due to metformin effect only. The PS distributions between metformin and non-metformin 
groups were compared graphically, showing no statistically significant areas of non-overlap 
which would otherwise violate the assumption of PS analysis (Supplementary Figure 2)(41).  
The primary analysis was Cox regression with PS adjustment. The PS adjusted 
absolute difference in GC risk between metformin and non-metformin users was calculated as 
follows: (adjusted HR – 1) x (crude incidence rate of GC in non-metformin users).(42)  
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Sensitivity analysis was conducted to assess robustness of the results, including 
multivariable analysis, PS adjustment after trimming of individuals in the non-overlapping 
parts of PS distribution,(43) PS weighting by inverse probability treatment weighting (IPTW) 
with stabilisation,(44) and PS matching without replacement in a 1:1 ratio.(45)  The 
description of these PS analysis methods was detailed in Supplementary Table 2. 
Standardised difference was used to assess the balance of the covariates between the two 
groups before and after IPTW and PS matching, and a value of below 0.2 indicated a 
negligible difference.(46) Supplementary Table 3 shows that most of the covariates were 
balanced after either IPTW or PS matching. Supplementary Figures 2 and 3 also show that 
PS distriubtion between the two groups became largely similar after PS matching. 
Similar statistical analyses were performed to determine the association between 
insulin use and GC. A two-sided p-value of < 0.05 was used to define statistical significance. 
The R packages ‘survival’ and ‘MatchIt’ were used for Cox regression analysis and PS 
matching, respectively.  
 
RESULTS 
Patient characteristics  
A total of 7,266 diabetic patients (type I: 30, type II: 3,394, unclassified: 3,842) who had 
received H. pylori eradication therapy during the study period were included. The median age 
 13 
of receiving clarithromycin-based triple therapy was 65.2 years (IQR:56.1–74.2), and 52.0% 
were male. There were 5,368 (73.9%) metformin users and the use of other diabetic 
medications was shown in Table 1.  
 
Risk of gastric cancer development and data validation  
During a median follow-up of 7.1 years (IQR: 4.7–9.8 years) (Table 1) totalling 52,208 
person-year, 37 (0.51%) patients were diagnosed to have GC (incidence rate: 7.1 per 10,000 
person-years), with 21 (56.8%) in the non-cardia region, 12 (32.4%) in the cardia and 
unspecified sites in the remaining 4 (10.8%) cases. The median age at GC diagnosis was 76.4 
years (IQR: 64.8–81.5 years). The median duration from receiving H. pylori eradication 
therapy to GC development was 4.4 years (IQR:3.1–6.8; metformin group: 5.1[IQR:3.5–7.6] 
vs non-metformin group: 3.9 [IQR:1.8–6.2]; p=0.117) (data not shown). 
 
Effect of metformin, insulin, and HbA1c on gastric cancer risk  
The median duration of metformin use was 5.5 years (IQR:3.3–8.4), and the median cDDD 
was 975 (IQR:436–1837). Among metformin users, 20 (0.37%) developed GC with an 
incidence rate of 4.9 per 10,000 person-years. There was a statistically significantly lower GC 
risk among metformin users (PS adjusted HR: 0.49; 95% CI:0.24–0.98) (Table 2). Sensitivity 
analysis by different statistical methods showed similar results (Table 2). The PS adjusted 
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absolute risk difference between metformin and non-metformin use was 7.60 fewer cancer 
cases (95% CI:0.30–11.33) per 10,000 person-years (data not shown). When patients with 
type I DM were excluded (n=7,236, GC =36), the PS adjusted HR was 0.47 (95% CI:0.23–
0.96). 
A total of 2,075 (28.6%) diabetic patients used insulin (Table 1). The median duration 
of insulin use was 4.7 years (IQR:1.3–7.2; metformin group: 4.7 [IQR:1.2–10.1] vs non-
metformin group: 4.9 [IQR:1.4–11.8]. The PS adjusted HR of GC with insulin use was 0.81 
(95% CI:0.35–1.85) (data not shown). 
In total, 11,286 HbA1c measurements were taken at baseline and during follow-up 
with a median of 13 measurements (IQR:7–22 times) per patient at a median interval of 4.7 
months (IQR:3.4–7.9) (data not shown). For the whole cohort, the median baseline and time-
weighted averaged HbA1c were 7.3% (IQR:6.5–8.7%) and 7.2% (IQR:6.6–7.9%), 
respectively. A higher proportion of metformin users had time-weighted HbA1c level ≥7% 
than non-metformin users (64.0% vs 39.7%) (Table 1). The corresponding median level of 
baseline HbA1c in the metformin and non-metformin groups was 7.4% (IQR: 6.6–8.9%) and 
6.8% (IQR: 6.1–8.0%), whereas the time-weighted averaged HbA1c was 7.3% (IQR: 6.8–
8.0%) and 6.7% (IQR: 6.2–7.6%), respectively (data not shown). Compared to patients with a 
time-weighted average HbA1c level of <7%, patients with a higher level did not have an 
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increased GC risk on either unadjusted (HR 0.83; 95% CI: 0.60–1.15) or multivariable 
analysis (HR 1.60; 95% CI: 0.78–3.27) (Table 3). 
 
Duration- and dose-response of metformin use and gastric cancer  
Table 4 shows the duration- and dose-response between metformin use and GC. A longer 
duration of metformin use was associated with a lower GC risk (HR: 0.85; 95% CI:0.74–0.96) 
for every one year increase in use. Compared with non-metformin users, those who used 
metformin for <3 years and ≥3 years had HRs of 0.75 (95% CI:0.32–1.74) and 0.35 (95% 
CI:0.16–0.80), respectively (ptrend=0.01). For dose effect, the HRs of GC with metformin use 
for <975 cDDD (median cDDD) and ≥975 cDDD, when compared with non-metformin use, 
were 0.73 (95% CI:0.35–1.53) and 0.33 (95% CI:0.13–0.86), respectively (ptrend=0.02).  
 
DISCUSSION 
In this territory-wide cohort study including more than 7,200 diabetic patients who had H. 
pylori eradicated, we showed that metformin use was associated with a 51% reduction in GC 
risk, with a clear dose- and duration-gradient association. Since GC risk was found to be 20% 
higher among diabetic patients(6) and eradication of H. pylori could only reduce GC risk by 
about 40%,(3, 4) there is a genuine need to identify novel chemopreventive agents for this 
specific group of high-risk patients. 
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The beneficial effects of metformin on GC prevention remains controversial as 
randomized clinical trials were lacking and previous observational studies yielded conflicting 
results.(10-16) Apart from the heterogeneity on definition of drug exposure, comparators and 
study design, failure to adjust for other important risk factors of GC including H. pylori 
infection, HbA1c level and concurrent medication use is likely the reason.(17) To address 
these limitations, our study included only diabetic patients who were successfully treated for 
H. pylori at baseline. This would remove the most important risk factor of H. pylori infection 
that could affect the effect estimate of metformin on GC risk. By including the time-weighted 
average HbA1c level into analysis, our study not only considered the baseline HbA1c level 
but also the dynamics of DM control throughout the follow-up so that a more precise effect 
estimate could be derived. In our study, a higher time-weighted average HbA1c level of ≥7% 
was not an independent risk factor for GC after H. pylori eradication. In contrary, a Japanese 
population-based cohort study showed that a higher HbA1c level acted synergistically with H. 
pylori infection in increasing GC risk(18). Notably, their study cohort differed from our 
current cohort of H. pylori-eradicated subjects, and no adjustments were made on the use of 
concurrent medications that could modulate GC risk, such as aspirin/NSAIDs(32), statins(34) 
and PPIs(35).  
We found that HbA1c levels were actually higher among metformin users, possibly 
related to the poor glycemic control necessitating metformin use. Yet, GC risk was 
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statistically significantly lower in the metformin group. Hence, our findings support the 
biological mechanisms underlying metformin in preventing GC, which is not mediated 
through improving glycemic control. Notably, although IGFs have been linked to GC 
development(40), insulin treatment was not associated with an increased GC risk in this study. 
The duration- and dose-response association observed further strengthened the possible 
chemopreventive effect of metformin on GC. A longer duration of metformin use was 
associated with a lower GC risk, which was consistent with the study by Kim et al showing 
the chemopreventive effect was only evident after ≥3 years of metformin use.(13)  
The strength of our study is the use of a comprehensive electronic public healthcare 
database that included drug prescription and dispensing records, reducing selection and 
information biases of observational studies.(32) The long follow-up duration (a median of 7 
years) also enables the assessment of GC with a long lag time. The robustment of the result is 
verified by the consistency from sensitivity analysis using various PS analysis methods which 
adjusted for a wide array of covariates. Notably, metformin users had more cormobidities 
than non-metformin users (Table 1). Given than all these covariates are potential risk factors 
of GC, the protective effects of statin against GC could only be underestimated. 
Several limitations of this study should be acknowledged. First, some risk factors like 
family history of GC and diet were not routinely captured in the CDARS. Second, as the 
success of H. pylori eradication was not documented in the ICD coding, we identified 
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patients with failure of clarithromycin-based triple therapy by the repeated prescription or 
prescription of second and third line therapies. Third, drug compliance could not be 
ascertained in this electronic database. However, medications are prescribed and dispensed 
together in the same hospital at a very low price (US$1.5 per item for 16 weeks), which can 
rule out the issue of non-dispensing due to cost issue. Further, non-compliance would only 
bias the beneficial effect of metformin towards null. Fourth, due to the long lag time and 
relatively low incidence of GC development after H. pylori eradication, there were only 37 
GC cases. Stratified analyses according to the cancer location (non-cardia and cardia) could 
not be performed. Lastly, information on GC staging was not available in the CDARS, 
precluding the exploration of potential effect of metformin on GC staging. 
In conclusion, our territory-wide study showed that among diabetic patients who had 
H. pylori-eradicated, metformin use was associated with a statistically significantly lower GC 
risk in a duration- and dose-response manner. This cancer protective effect was independent 
of glycemic control.  
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Tables 
 
Table 1. Baseline characteristics of study cohort (n=7,266) 
Characteristic 
All, No. (%) 
(n=7,266) 
Metformin 
users, No. (%) 
(n=5,368) 
Non-metformin 
users, No. (%) 
(n=1,898) 
Median age at triple therapy, y 
(IQR) 
65.2 (56.1 74.2) 63.8 (55.6-72.6) 69.7 (58.2–78.2) 
Male sex 3779 (52.0) 2716 (50.6) 1063 (56.0) 
Median duration of follow-up, y 
(IQR) 
7.1 (4.7 – 9.8) 7.5 (5.2 – 10.1) 5.8 (3.5 – 8.8) 
Time-weighted average HbA1c ≥ 
7% 
4191 (57.7) 3437 (64.0) 754 (39.7) 
Smoking 1265 (17.4) 945 (17.6) 320 (16.9) 
Alcohol 116 (1.6) 61 (1.1) 55 (2.9) 
History of gastric ulcer 281 (3.9) 180 (3.4) 101 (5.3) 
History of duodenal ulcer 295 (4.1) 198 (3.7) 97 (5.1) 
Hypertension 4503 (62.0) 3246 (60.5) 1257 (66.2) 
Dyslipidemia 1982 (27.3) 1483 (27.6) 499 (26.3) 
Obesity 1288 (17.7) 1097 (20.4) 191 (10.1) 
Ischemic heart disease 1864 (25.7) 1318 (24.6) 546 (28.8) 
Atrial fibrillation 649 (8.9) 426 (7.9) 223 (11.7) 
Congestive heart failure 1001 (13.8) 579 (10.8) 422 (22.2) 
Stroke 1341 (18.5) 935 (17.4) 406 (21.4) 
Chronic renal failure 770 (10.6) 346 (6.4) 424 (22.3) 
Cirrhosis 274 (3.8) 148 (2.8) 126 (6.6) 
Aspirin/ NSAIDs/COX-2 
inhibitors* 
3457 (47.6) 2649 (49.3) 808 (42.6) 
Statins* 4375 (60.2) 3562 (66.4) 813 (42.8) 
Proton pump inhibitors* 966 (13.3) 654 (12.2) 312 (16.4) 
Insulin* 2075 (28.6) 1575 (29.3) 500 (26.3) 
Sulphonylureas* 4004 (74.6) 4004 (74.6) 772 (40.7) 
Acarbose* 279 (3.8) 239 (4.5) 40 (2.1) 
Glitazones* 288 (4.0) 254 (4.7) 34 (1.8) 
Dipeptidyl peptidase IV inhibitors* 842 (11.6) 781 (14.5) 61 (3.2) 
HbA1c, hemoglobin A1c; NSAIDs, non-steroidal anti-inflammatory drugs; COX-2, 
cyclooxygenase-2;  
* Drug use was defined as use for more than 180 days 
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Table 2. Association between metformin use* and gastric cancer (GC) risk  
 
Analysis 
No. of 
patients 
No. of GC 
events 
HR of GC with 
metformin use 
(95% CI) 
p-
value† 
Unadjusted analysis 7266 37 0.32 (0.17 – 0.61) < 0.001 
Multivariable analysis 7266 37 0.46 (0.23 – 0.93) 0.03 
PS adjustment (without 
trimming) 
7266 37 0.49 (0.24 – 0.98) 0.045 
PS adjustment after trimming 7253 37 0.49 (0.24 – 0.98) 0.045 
PS weighting by inverse 
probability treatment weighting 
7266 37 0.47 (0.23 – 0.96) 0.034 
PS matching 3608 24 0.36 (0.15 – 0.87) 0.02 
HR, hazard ratio;  CI, confidence interval; PS, propensity score  
*Metformin use was defined as use for more than 180 days 
†Cox proportional hazards model was used to calculate the P values, and the test was two-
sided. 
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Table 3. Association between metformin, insulin, time-weighted average HbA1c and 
gastric cancer risk  
 
Variables 
Unadjusted  analysis Multivariable analysis* 
HR (95% CI) p-value† HR (95% CI) p-value† 
Metformin‡ 0.32 (0.17 – 0.61) < 0.001 0.46 (0.23 – 0.93) 0.03 
Insulin‡ 0.80 (0.38 – 1.70) 0.57 0.76 (0.33 – 1.75) 0.52 
Time-weighted average 
HbA1c ≥ 7% 
0.83 (0.60 – 1.15) 0.27 1.60 (0.78 – 3.27) 0.20 
CI, confidence interval; HR, hazard ratio; HbA1c, hemoglobin A1c 
* Adjusted for age at triple therapy, sex, smoking, alcoholism, history of gastric ulcer, history 
of duodenal ulcer, other comorbidities (hypertension, dyslipidemia, obesity, ischemic heart 
disease, atrial fibrillation, congestive heart failure, stroke, chronic renal failure, cirrhosis) and 
concurrent medications (statins, aspirin/non-steroidal anti-inflammatory 
drugs/cyclooxygenase-2 inhibitors, proton pump inhibitors)  
†Cox proportional hazards model was used to calculate the P values, and the test was two-
sided. 
‡Drug use was defined as use for more than 180 days 
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Table 4. Association between duration and dose of metformin use and gastric cancer 
risk (propensity score adjustment) 
Duration and dose HR (95% CI) p-value* Ptrend† 
Duration    
Per every 1 yr increase in 
use‡ 
0.85 (0.74 – 0.96) 0.01  
Metformin use§    
Non-metformin users 1.00 (Reference)   
< 3 years 0.75 (0.32 – 1.74) 0.51 0.01 
≥ 3 years 0.35 (0.16 – 0.80) 0.01  
Dose    
Non-metformin users 1.00 (Reference) -  
< median, 975 cDDD 0.73 (0.35 – 1.53) 0.40 0.02 
≥ median, 975 cDDD 0.33 (0.13 – 0.86) 0.02  
HR, hazard ratio; 95% CI, 95% confidence interval; cDDD, cumulative Defined Daily Dose 
*Cox proportional hazards model was used to calculate the P values, and the test was two-
sided. 
†Cox proportional hazards model was used to calculate the P values, and the test was two-
sided. 
 
‡Continuous variable 
§Categorical variable 
 
